Safety and Tolerability Cerebrolysin: Well-Established Safety Profile Cerebrolysin benefits from decades of post-marketing surveillance and clinical trial safety data: Clinical Trial Safety: Across multiple RCTs, Cerebrolysin has demonstrated a tolerability profile comparable to placebo in most studies, with adverse events generally mild and transient Common Side Effects: Injection site reactions, dizziness, headache, and nausea are the most frequently reported adverse events at standard clinical doses Serious Adverse Events: Rare at therapeutic doses
Long-term human safety data are limited because BPC-157 is not FDA-approved
Specialist consultation mandatory
Repetitive computer work, manual labor, cooking, gardening, and countless other activities can trigger the same degenerative process in these tendons
If folate deficiency is suspected, it is reasonable to give oral folic acid (0.4 1 mg/day) without doing laboratory investigation for deficiency at least until the hemoglobin and mean corpuscular volume normalizes (or longer if the underlying cause cannot be eliminated)
Without baseline labs, you cannot know whether the peptide is working